ROE: High-Quality ETF With Improved Performance, GARP Tilt, A Buy (Rating Upgrade)

Astoria US Equal Weight Quality Kings ETF is being upgraded to Buy as performance has improved significantly since December 2024. The fund’s high-quality portfolio now carries a GARP tilt with a 0.67 weighted-average PEG ratio, supporting a more constructive view on fundamentals. The note is primarily analyst commentary and is unlikely to have broad market impact.

Analysis

This is less a pure quality factor call than a regime signal: the portfolio is drifting into a GARP sweet spot where earnings durability and multiple support can coexist. That matters because in a late-cycle, slower-growth tape, the market often stops paying up for “best businesses” alone and instead rewards names that can compound through modest growth plus acceptable valuation. The improved performance since December suggests the strategy has moved from factor headwind to a cleaner expression of defensiveness with upside participation, which tends to attract incremental allocators once short-horizon underperformance fear fades.

Second-order, the likely winners are not just the holdings but the capital that benchmarks against them. If this vehicle continues to gather assets, it can pressure adjacent high-quality but richer large-cap growth exposures as allocators rebalance toward a cheaper quality basket with similar balance-sheet characteristics. That can create a relative valuation squeeze in mega-cap quality names that are still priced as secular growers, while cyclicals with temporarily high ROE but weak earnings quality remain vulnerable as investors differentiate between “high return” and “high durability.”

The main risk is that the GARP tilt is backward-looking if PEG compression came from falling estimates rather than improving fundamentals. Over the next 1-3 months, any uptick in rates or a growth scare could help the factor in absolute terms, but over 6-12 months the strategy needs real EPS delivery to avoid becoming a crowded quasi-defensive trade. If earnings revisions roll over, the market will quickly re-rate this from quality growth to expensive defense.

Consensus may be underestimating how much active positioning matters here: an equal-weight quality sleeve can outperform not because it owns the best stocks, but because it avoids concentration risk in the few over-owned winners. The underappreciated edge is that this structure should be less sensitive to single-name multiple compression and more resilient in dispersion-heavy markets. That makes it attractive as a portfolio ballast, but not a set-and-forget hold if the broader market re-accelerates and low-quality beta comes back into favor.

Key Decisions for Investors

• Add a tactical long in ROE over the next 2-6 weeks as a quality/GARP diversifier, but size it as a hedge rather than a core beta expression; target outperformance if rates stay range-bound and revisions remain stable.
• Pair trade: long ROE vs short a concentrated large-cap growth ETF or basket over 1-3 months to capture relative valuation mean reversion if the market continues rewarding cheaper quality over duration-heavy growth.
• If already long quality factors, trim names with the highest PEG compression risk and rotate into lower-multiple, cash-generative holdings within the same factor bucket; prefer 6-12 month compounding over multiple expansion.
• Use a stop/review trigger on 1Q earnings revision trends: if forward EPS estimates for the underlying basket start to fall for 2 consecutive weeks, reduce exposure by 25-50% as the GARP case weakens materially.